Icon Plc $ICLR Shares Purchased by Daiwa Securities Group Inc.

Daiwa Securities Group Inc. lifted its position in Icon Plc (NASDAQ:ICLR) by 16.7% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 34,994 shares of the medical research company’s stock after acquiring an additional 5,018 shares during the period. Daiwa Securities Group Inc.’s holdings in Icon were worth $6,377,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently made changes to their positions in ICLR. Toth Financial Advisory Corp acquired a new stake in shares of Icon in the fourth quarter worth approximately $27,000. Ameriflex Group Inc. acquired a new stake in shares of Icon in the third quarter worth approximately $33,000. Johnson Financial Group Inc. acquired a new stake in shares of Icon in the third quarter worth approximately $71,000. Quadrant Capital Group LLC acquired a new stake in shares of Icon in the third quarter worth approximately $78,000. Finally, Geneos Wealth Management Inc. boosted its stake in shares of Icon by 11.5% in the second quarter. Geneos Wealth Management Inc. now owns 541 shares of the medical research company’s stock worth $79,000 after acquiring an additional 56 shares during the last quarter. 95.61% of the stock is owned by institutional investors and hedge funds.

Icon Stock Performance

Shares of Icon stock opened at $149.45 on Monday. Icon Plc has a one year low of $66.57 and a one year high of $211.00. The company has a market cap of $11.44 billion, a price-to-earnings ratio of 24.26, a PEG ratio of 11.81 and a beta of 1.26. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.10 and a current ratio of 1.10. The business’s 50 day moving average price is $117.51 and its 200 day moving average price is $140.74.

Icon (NASDAQ:ICLR) last announced its quarterly earnings data on Wednesday, May 27th. The medical research company reported $2.21 EPS for the quarter. Icon had a return on equity of 9.50% and a net margin of 5.98%.The firm had revenue of $2.11 billion for the quarter. Icon has set its FY 2026 guidance at 10.000-11.000 EPS. On average, research analysts predict that Icon Plc will post 9.74 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on ICLR shares. Piper Sandler lowered Icon to a “neutral” rating in a research note on Thursday, May 28th. Bank of America reiterated an “outperform” rating on shares of Icon in a research report on Monday, June 1st. Leerink Partners set a $145.00 price objective on Icon in a research report on Thursday, May 28th. Weiss Ratings downgraded Icon from a “sell (d+)” rating to a “sell (d)” rating in a research report on Friday, May 29th. Finally, Zacks Research downgraded Icon from a “hold” rating to a “strong sell” rating in a research report on Wednesday, February 25th. Eight analysts have rated the stock with a Buy rating, eight have issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat, Icon currently has a consensus rating of “Hold” and an average target price of $156.44.

About Icon

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.